Potent and selective LRRK2 inhibitor (IC50 values are 2.2, 6.6 and 47.7 nM for G2019S-mutant, wild-type and A2016T-mutant LRRK2, respectively). Selective for LRRK2 over a panel of 138 kinases. Brain penetrant and orally bioavailable.
Sold under license from Dana-Farber Cancer Institute.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 416.87. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.4 mL||11.99 mL||23.99 mL|
|5 mM||0.48 mL||2.4 mL||4.8 mL|
|10 mM||0.24 mL||1.2 mL||2.4 mL|
|50 mM||0.05 mL||0.24 mL||0.48 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Hatcher et al (2015) Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor. ACS Med.Chem.Lett. 6 584 PMID: 26005538
If you know of a relevant reference for JH-II-127, please let us know.
View Related Products by Product Action
Keywords: JH-II-127, supplier, potent, selective, Leucine-rich, repeat, kinase, 2, LRRK2, inhibitor, inhibits, orally, bioavaillable, brain, penetrant, Parkinson's, parkinsons, LRRK2, Tocris Bioscience
Citations for JH-II-127
Citations are publications that use Tocris products.
Currently there are no citations for JH-II-127. Do you know of a great paper that uses JH-II-127 from Tocris? If so please let us know.
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.